MX358097B - Formulaciones liquidas de apixaban. - Google Patents
Formulaciones liquidas de apixaban.Info
- Publication number
- MX358097B MX358097B MX2015003393A MX2015003393A MX358097B MX 358097 B MX358097 B MX 358097B MX 2015003393 A MX2015003393 A MX 2015003393A MX 2015003393 A MX2015003393 A MX 2015003393A MX 358097 B MX358097 B MX 358097B
- Authority
- MX
- Mexico
- Prior art keywords
- liquid formulations
- apixaban liquid
- apixaban
- liquid formulation
- formulations
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003886 apixaban Drugs 0.000 title abstract 3
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona una formulación líquida de apixaban. También se proporciona un método de administrar una formulación líquida de apixaban.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261705943P | 2012-09-26 | 2012-09-26 | |
US201361773032P | 2013-03-05 | 2013-03-05 | |
PCT/US2013/062051 WO2014052678A1 (en) | 2012-09-26 | 2013-09-26 | Apixaban liquid formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015003393A MX2015003393A (es) | 2015-09-25 |
MX358097B true MX358097B (es) | 2018-08-06 |
Family
ID=49447800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003393A MX358097B (es) | 2012-09-26 | 2013-09-26 | Formulaciones liquidas de apixaban. |
Country Status (18)
Country | Link |
---|---|
US (2) | US9452134B2 (es) |
EP (1) | EP2900217A1 (es) |
JP (1) | JP6248112B2 (es) |
KR (1) | KR102035373B1 (es) |
CN (1) | CN104736142B (es) |
AU (1) | AU2013323435C1 (es) |
BR (1) | BR112015005995A2 (es) |
CA (1) | CA2885899A1 (es) |
HK (1) | HK1212900A1 (es) |
IL (1) | IL237804A0 (es) |
IN (1) | IN2015DN01902A (es) |
MX (1) | MX358097B (es) |
MY (1) | MY179191A (es) |
NZ (1) | NZ630763A (es) |
PH (1) | PH12015500590A1 (es) |
RU (1) | RU2660358C2 (es) |
SG (2) | SG11201501743UA (es) |
WO (1) | WO2014052678A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
EP4353312A2 (en) * | 2018-04-16 | 2024-04-17 | Bristol-Myers Squibb Company | Apixaban formulations |
EP3838265A4 (en) | 2018-08-14 | 2022-05-11 | Jiangsu Hengrui Medicine Co., Ltd. | INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION |
US20240041856A1 (en) | 2020-12-13 | 2024-02-08 | Dafechem Limited | Liquid apixaban formulation in small dose volume |
CN113384526A (zh) * | 2021-08-03 | 2021-09-14 | 合肥医工医药股份有限公司 | 一种稳定的阿哌沙班口服溶液制剂及其制备方法 |
AU2022374714B2 (en) | 2021-10-27 | 2024-05-23 | Pharma-Data S.A. | Apixaban suspension and preparation method |
NL2029536B1 (en) | 2021-10-27 | 2023-05-26 | Pharma Data S A | Apixaban suspension and preparation method |
US20230285368A1 (en) * | 2022-03-09 | 2023-09-14 | Slayback Pharma Llc | Stable pharmaceutical compositions of apixaban |
WO2023218482A1 (en) * | 2022-05-09 | 2023-11-16 | Syri Research Private Limited | Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof |
US11833138B1 (en) | 2023-01-30 | 2023-12-05 | Tap Pharmaceuticals Ag | Liquid pharmaceutical formulations of apixaban |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763449A (en) * | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
EP1738749A1 (en) | 1999-12-23 | 2007-01-03 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
JP4249621B2 (ja) * | 2001-09-21 | 2009-04-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第Xa因子阻害剤としてのラクタム含有化合物およびその誘導体 |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
AU2005328349A1 (en) * | 2005-02-25 | 2006-09-08 | Biomarin Pharmaceutical Inc. | Room temperature stable aqueous liquid pharmaceutical composition |
US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
AU2009205314A1 (en) * | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
PT3100728T (pt) * | 2009-05-13 | 2020-02-21 | Cydex Pharmaceuticals Inc | Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos |
SG176785A1 (en) * | 2009-06-16 | 2012-01-30 | Pfizer | Dosage forms of apixaban |
CN102770126A (zh) * | 2010-02-25 | 2012-11-07 | 百时美施贵宝公司 | 阿哌沙班制剂 |
EP2484775A1 (de) | 2011-02-07 | 2012-08-08 | Siemens Healthcare Diagnostics Products GmbH | Heparin-insensitives Verfahren zur Bestimmung von direkten Gerinnungsfaktorinhibitoren |
RU2638155C1 (ru) * | 2016-02-29 | 2017-12-12 | Общество С Ограниченной Ответственностью "Сай Фарма" | Производные бензо[d]изоксазола и их применение |
-
2013
- 2013-09-26 SG SG11201501743UA patent/SG11201501743UA/en unknown
- 2013-09-26 SG SG10201702048VA patent/SG10201702048VA/en unknown
- 2013-09-26 KR KR1020157007276A patent/KR102035373B1/ko active IP Right Grant
- 2013-09-26 IN IN1902DEN2015 patent/IN2015DN01902A/en unknown
- 2013-09-26 MY MYPI2015000670A patent/MY179191A/en unknown
- 2013-09-26 MX MX2015003393A patent/MX358097B/es active IP Right Grant
- 2013-09-26 AU AU2013323435A patent/AU2013323435C1/en active Active
- 2013-09-26 CA CA2885899A patent/CA2885899A1/en not_active Abandoned
- 2013-09-26 US US14/430,275 patent/US9452134B2/en active Active
- 2013-09-26 CN CN201380049617.6A patent/CN104736142B/zh active Active
- 2013-09-26 WO PCT/US2013/062051 patent/WO2014052678A1/en active Application Filing
- 2013-09-26 RU RU2015115127A patent/RU2660358C2/ru active
- 2013-09-26 JP JP2015534679A patent/JP6248112B2/ja not_active Expired - Fee Related
- 2013-09-26 EP EP13779656.1A patent/EP2900217A1/en not_active Withdrawn
- 2013-09-26 BR BR112015005995A patent/BR112015005995A2/pt not_active Application Discontinuation
- 2013-09-26 NZ NZ630763A patent/NZ630763A/en unknown
-
2015
- 2015-03-18 IL IL237804A patent/IL237804A0/en unknown
- 2015-03-18 PH PH12015500590A patent/PH12015500590A1/en unknown
-
2016
- 2016-01-27 HK HK16100889.6A patent/HK1212900A1/zh unknown
- 2016-05-24 US US15/162,985 patent/US10016362B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG10201702048VA (en) | 2017-04-27 |
JP6248112B2 (ja) | 2017-12-13 |
PH12015500590B1 (en) | 2015-05-25 |
AU2013323435B2 (en) | 2017-10-19 |
PH12015500590A1 (en) | 2015-05-25 |
MY179191A (en) | 2020-10-30 |
RU2015115127A (ru) | 2016-11-20 |
NZ630763A (en) | 2017-01-27 |
CN104736142B (zh) | 2020-03-03 |
KR102035373B1 (ko) | 2019-10-22 |
HK1212900A1 (zh) | 2016-06-24 |
BR112015005995A2 (pt) | 2017-07-04 |
AU2013323435A1 (en) | 2014-04-03 |
RU2660358C2 (ru) | 2018-07-05 |
US9452134B2 (en) | 2016-09-27 |
KR20150058243A (ko) | 2015-05-28 |
JP2015531377A (ja) | 2015-11-02 |
US20160263097A1 (en) | 2016-09-15 |
MX2015003393A (es) | 2015-09-25 |
US20150224053A1 (en) | 2015-08-13 |
US10016362B2 (en) | 2018-07-10 |
IN2015DN01902A (es) | 2015-08-07 |
AU2013323435C1 (en) | 2018-04-12 |
SG11201501743UA (en) | 2015-04-29 |
CN104736142A (zh) | 2015-06-24 |
AU2013323435A8 (en) | 2015-04-23 |
IL237804A0 (en) | 2015-05-31 |
CA2885899A1 (en) | 2014-04-03 |
EP2900217A1 (en) | 2015-08-05 |
WO2014052678A1 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500590A1 (en) | Apixaban liquid formulations | |
PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
IN2014MN02598A (es) | ||
UY34698A (es) | Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos | |
UY34105A (es) | Formulación líquida estable de etanercept | |
MX2015002669A (es) | Metodos de administracion de tratamiento con pirfenidona. | |
IN2015DN03029A (es) | ||
BR112014026926A2 (pt) | uso terapêutico de produtos de semente de chardonnay | |
PL2773648T3 (pl) | Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile | |
IN2014DN06169A (es) | ||
CO7151499A2 (es) | Formulación inyectable | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
CO7141434A2 (es) | Nueva forma de dosificación formulación de abediterol | |
SI2812013T1 (sl) | Formulacija za zdravljenje SRČ-ja | |
MY166052A (en) | Freeze-Dried Aripiprazole Formulation | |
CO7200262A2 (es) | Nueva dosificación y formulación | |
IN2014DN10658A (es) | ||
CO7151505A2 (es) | Formulación oral | |
BR112013027390A2 (pt) | formulação farmacêutica | |
HK1216843A1 (zh) | 用於施用奧昔布寧的方法和組合物 | |
MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
IN2013MU02279A (es) | ||
UA71418U (uk) | 5,7-ДИМЕТИЛ-6-ФЕНІЛАЗО-3H-ТІАЗОЛО[4,5-b]ПІРИДИН-2-ОН, ЩО ПРОЯВЛЯЄ АНТИЕКСУДАТИВНУ ДІЮ | |
UA65038U (ru) | Способ лечения больных послеродовыми психозами |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: PFIZER INC. |
|
FG | Grant or registration |